​

​

​

Technology

 

Recōdagen is a drug development company advancing novel treatments for cancer and other life-threatening diseases. Founded by leading experts in disease-specific and developmental gene expressions, Recōdagen strives to improve the lives of all patients and while providing cost effective therapies.

Epithelial cell derived cancers, such as prostate, lung, endometrial, breast and melanoma, are devastating illnesses for both patients and their families.  Current therapies cause serious negative side effects.  Today, so-called “targeted therapies” typically target a protein that is also found on normal cells.  In contrast, Recōdagen’s lead target is not just protein specific but is cancer-specific.  The only normal cell type that expresses this target occurs during early pregnancy.  Therefore, our therapies will strictly target cancer cells while normal cells will likely be spared. 

 

Mig7 and our other targets are from our platform strategy that utilizes proprietary knowledge of how previously deemed long "noncoding" RNAs from the dark matter genome do encode proteins.  These genomic transcripts and their proteins tend to be expressed cell- and disease-specifically.

​

Additional targets to treat diseases such as Alzheimer’s and autoimmunity have been determined.

“Recōdagen” represents the atypical mechanisms by which the proteins we target are made.